Most cited papers from Philogen (Italy)

Philogen (Italy)

What are the most cited papers from Philogen (Italy)?

The most cited paper from Philogen (Italy) is "Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin" (Laura Borsi, Enrica Balza, Marco Bestagno et al., 2002), with 360 citations. Next come "DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges" (329) and "Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer." (294).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 12 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin Laura Borsi, Enrica Balza, Marco Bestagno et al. · International Journal of Cancer Open access	25 Sep 2002	360
2	DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges Adrián Gironda-Martínez, Etienne J. Donckèle, Florent Samain et al. · ACS Pharmacology & Translational Science Open access	14 Jun 2021	329
3	Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Monica Santimaria, Giovanni Moscatelli, Giuseppe Viale et al. · PubMed	Feb 2003	294
4	The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma Manfred Johannsen et al. · European Journal of Cancer	25 Aug 2010	188
5	Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study Riccardo Danielli, Roberto Patuzzo, Anna Maria Di Giacomo et al. · Cancer Immunology Immunotherapy Open access	13 May 2015	183
6	Design, construction, and characterization of a large synthetic human antibody phage display library Michela Silacci, Simon Brack, Giulia Schirru et al. · PROTEOMICS	6 May 2005	177
7	Expression of the oncofetal ED-B–containing fibronectin isoform in hematologic tumors enables ED-B–targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients Stefanie Sauer, Paola Anna Erba, Mario Petrini et al. · Blood	9 Jan 2009	173
8	An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications Jacopo Millul, Gabriele Bassi, Jacqueline Mock et al. · Proceedings of the National Academy of Sciences Open access	13 Apr 2021	168
9	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma Thomas Eigentler, Benjamin Weide, Filippo de Braud et al. · Clinical Cancer Research	25 Oct 2011	151
10	Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy Jessica Mårlind, Manuela Kaspar, Eveline Trachsel et al. · Clinical Cancer Research	15 Oct 2008	124
11	Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia Katrin L. Gutbrodt, Christoph Schliemann, Leonardo Giovannoni et al. · Science Translational Medicine	4 Sep 2013	111
12	Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA Philipp Backhaus et al. · European Journal of Nuclear Medicine and Molecular Imaging Open access	26 Dec 2021	108
13	Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate Dietmar Berndorff, Sandra Borkowski, Stephanie Sieger et al. · Clinical Cancer Research Open access	Oct 2005	106
14	Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours Gianluca Spitaleri, Rossana Berardi, Chiara Pierantoni et al. · Journal of Cancer Research and Clinical Oncology Open access	16 Nov 2012	101
15	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Benjamin Weide, Thomas Eigentler, Annette Pflugfelder et al. · Cancer Immunology Research	5 Apr 2014	97
16	The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity Teresa Hemmerle, Philipp Probst, Leonardo Giovannoni et al. · British Journal of Cancer Open access	25 Jul 2013	96
17	Isolated limb perfusion with the tumor‐targeting human monoclonal antibody–cytokine fusion protein L19‐TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma Francesco Saverio Papadia, Valéria Basso, Roberto Patuzzo et al. · Journal of Surgical Oncology	4 Jun 2012	86
18	The antibody‐based targeted delivery of interleukin‐4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer Teresa Hemmerle, Dario Neri · International Journal of Cancer Open access	2 Jul 2013	83
19	A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake Andrea Galbiati, Aureliano Zana, Matilde Bocci et al. · Journal of Nuclear Medicine Open access	19 May 2022	81
20	Plant pharming of a full‐sized, tumour‐targeting antibody using different expression strategies Maria Elena Villani, Богдан Володимирович Моргун, Patrizia Brunetti et al. · Plant Biotechnology Journal Open access	12 Sep 2008	80
21	Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study Gian Luca Poli, Claudia Bianchi, Giorgio Virotta et al. · Cancer Immunology Research Open access	21 May 2013	79
22	Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells Thore Dietrich, Thomas Hucko, Christiane Schneemann et al. · Atherosclerosis	7 Oct 2011	77
23	Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies Paola Anna Erba, Martina Sollini, Enrico Orciuolo et al. · Journal of Nuclear Medicine Open access	10 May 2012	76
24	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer Chiara Catania, Michela Maur, Rossana Berardi et al. · Cell Adhesion & Migration Open access	2 Jan 2015	64
25	Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients Derrek A. Heuveling, Remco de Bree, Daniëlle J. Vugts et al. · Journal of Nuclear Medicine Open access	18 Jan 2013	49
26	Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation Christoph Schliemann, Katrin L. Gutbrodt, Andrea Kerkhoff et al. · Cancer Immunology Research	12 Feb 2015	46
27	Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12 Roberto Sommavilla, Nadine Pasche, Eveline Trachsel et al. · Protein Engineering Design and Selection Open access	15 Jun 2010	43
28	Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ Dirk Faulhammer, Bernd Eschgfäller, Sandra C. Stark et al. · RNA Open access	17 Feb 2004	42
29	Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening Leonardo Giovannoni · Nucleic Acids Research Open access	Mar 2001	42
30	Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma Thomas A. Look, Emanuele Puca, Marcel Bühler et al. · Science Translational Medicine	24 May 2023	40
31	A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition Sebastian Oehler, Laura Lucaroni, Francesca Migliorini et al. · Nature Chemistry	3 Jul 2023	37
32	Preclinical Evaluation of 177 Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors Andrea Galbiati, Matilde Bocci, Domenico Ravazza et al. · Journal of Nuclear Medicine Open access	12 Sep 2024	36
33	A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule–Drug, Antibody–Drug, and Peptide–Drug Conjugates Aureliano Zana, Claudia Puig-Moreno, Matilde Bocci et al. · Bioconjugate Chemistry	3 Jul 2023	35
34	Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma Luigi Aloj, Laura D’Ambrosio, Michela Aurilio et al. · European Journal of Nuclear Medicine and Molecular Imaging	16 Jan 2014	35
35	In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment Matilde Bocci, Aureliano Zana, Lucrezia Principi et al. · Journal of Controlled Release	13 Feb 2024	33
36	Membranal and Blood‐Soluble HLA Class II Peptidome Analyses Using Data‐Dependent and Independent Acquisition Danilo Ritz, Emiliano Sani, Hanna Dêbiec et al. · PROTEOMICS Open access	3 Jan 2018	33
37	F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach Stefan T. G. Bruijnen, Durga M. S. H. Chandrupatla, Leonardo Giovanonni et al. · Molecular Pharmaceutics Open access	14 Dec 2018	31
38	Armed antibodies for cancer treatment: a promising tool in a changing era Riccardo Danielli, Roberto Patuzzo, Pier Adelchi Ruffini et al. · Cancer Immunology Immunotherapy Open access	14 Oct 2014	31
39	A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells Klaus Zuberbühler, Alessandro Palumbo, Cristina Bacci et al. · Protein Engineering Design and Selection Open access	16 Oct 2008	30
40	Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient Ricarda Johanna Locher, Paola Anna Erba, Burkhard Hirsch et al. · Journal of Cancer Research and Clinical Oncology Open access	16 Oct 2013	30
41	Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention Andrea Galbiati, Matilde Bocci, Silvia I. Gervasoni et al. · Journal of Medicinal Chemistry Open access	30 Jul 2024	28
42	Fibroblast Activation Protein Triggers Release of Drug Payload from Non-internalizing Small Molecule Drug Conjugates in Solid Tumors Aureliano Zana, Andrea Galbiati, Ettore Gilardoni et al. · Clinical Cancer Research	10 Oct 2022	28
43	Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody Lisa Nadal et al. · Journal for ImmunoTherapy of Cancer Open access	Sep 2022	27
44	Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy Tony Georgiev, Francesca Migliorini, Andrea Ciamarone et al. · Nature Biomedical Engineering	26 Jun 2025	24
45	Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature Niklas Börschel, Christian Schwöppe, Caroline Zerbst et al. · Leukemia Research	18 Apr 2015	23
46	Small Organic Carbonic Anhydrase IX Ligands from DNA-Encoded Chemical Libraries for Tumor-Targeted Delivery of Radionuclides Marco Müller, Tony Georgiev, Jacqueline Mock et al. · Journal of the American Chemical Society	16 May 2025	22
47	Deep Learning Approach for the Discovery of Tumor-Targeting Small Organic Ligands from DNA-Encoded Chemical Libraries Wen Torng, Ilaria Biancofiore, Sebastian Oehler et al. · ACS Omega Open access	6 Jul 2023	22
48	Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy Francesco Bartoli, Philip H. Elsinga, Luiza Reali Nazario et al. · Pharmaceuticals Open access	2 Aug 2022	22
49	Past, present and future of drug conjugates for cancer therapy Samuele Cazzamalli, Emanuele Puca, Dario Neri · Nature Cancer	11 Sep 2025	19
50	Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas Christoph Schliemann, Teresa Hemmerle, Andrew F. Berdel et al. · European Journal of Cancer	23 Apr 2021	19

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.